Literature DB >> 34070849

Rare Germline Variants in Chordoma-Related Genes and Chordoma Susceptibility.

Sally Yepes1, Nirav N Shah1, Jiwei Bai2, Hela Koka1, Chuzhong Li2, Songbai Gui2, Mary Lou McMaster1, Yanzi Xiao1, Kristine Jones1,3, Mingyi Wang1,3, Aurelie Vogt1,3, Bin Zhu1,3, Bin Zhu1,3, Amy Hutchinson1,3, Meredith Yeager1,3, Belynda Hicks1,3, Brian Carter4, Neal D Freedman1, Laura Beane-Freeman1, Stephen J Chanock1, Yazhuo Zhang2, Dilys M Parry1, Xiaohong R Yang1, Alisa M Goldstein1.   

Abstract

BACKGROUND: Chordoma is a rare bone cancer with an unknown etiology. TBXT is the only chordoma susceptibility gene identified to date; germline single nucleotide variants and copy number variants in TBXT have been associated with chordoma susceptibility in familial and sporadic chordoma. However, the genetic susceptibility of chordoma remains largely unknown. In this study, we investigated rare germline genetic variants in genes involved in TBXT/chordoma-related signaling pathways and other biological processes in chordoma patients from North America and China.
METHODS: We identified variants that were very rare in general population and internal control datasets and showed evidence for pathogenicity in 265 genes in a whole exome sequencing (WES) dataset of 138 chordoma patients of European ancestry and in a whole genome sequencing (WGS) dataset of 80 Chinese patients with skull base chordoma.
RESULTS: Rare and likely pathogenic variants were identified in 32 of 138 European ancestry patients (23%), including genes that are part of notochord development, PI3K/AKT/mTOR, Sonic Hedgehog, SWI/SNF complex and mesoderm development pathways. Rare pathogenic variants in COL2A1, EXT1, PDK1, LRP2, TBXT and TSC2, among others, were also observed in Chinese patients.
CONCLUSION: We identified several rare loss-of-function and predicted deleterious missense variants in germline DNA from patients with chordoma, which may influence chordoma predisposition and reflect a complex susceptibility, warranting further investigation in large studies.

Entities:  

Keywords:  WES; WGS; cancer susceptibility; chordoma; germline variants; notochord development

Year:  2021        PMID: 34070849     DOI: 10.3390/cancers13112704

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  30 in total

1.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

Review 2.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

3.  ClinVar: improvements to accessing data.

Authors:  Melissa J Landrum; Shanmuga Chitipiralla; Garth R Brown; Chao Chen; Baoshan Gu; Jennifer Hart; Douglas Hoffman; Wonhee Jang; Kuljeet Kaur; Chunlei Liu; Vitaly Lyoshin; Zenith Maddipatla; Rama Maiti; Joseph Mitchell; Nuala O'Leary; George R Riley; Wenyao Shi; George Zhou; Valerie Schneider; Donna Maglott; J Bradley Holmes; Brandi L Kattman
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

4.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Authors:  J K Gohagan; P C Prorok; R B Hayes; B S Kramer
Journal:  Control Clin Trials       Date:  2000-12

5.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Authors:  Wesley Hsu; Ahmed Mohyeldin; Sagar R Shah; Colette M ap Rhys; Lakesha F Johnson; Neda I Sedora-Roman; Thomas A Kosztowski; Ola A Awad; Edward F McCarthy; David M Loeb; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

6.  T (brachyury) gene duplication confers major susceptibility to familial chordoma.

Authors:  Xiaohong R Yang; David Ng; David A Alcorta; Norbert J Liebsch; Eamonn Sheridan; Sufeng Li; Alisa M Goldstein; Dilys M Parry; Michael J Kelley
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

7.  Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Authors:  Sagar R Shah; Justin M David; Nathaniel D Tippens; Ahmed Mohyeldin; Juan C Martinez-Gutierrez; Sara Ganaha; Paula Schiapparelli; Duane H Hamilton; Claudia Palena; Andre Levchenko; Alfredo Quiñones-Hinojosa
Journal:  Cell Rep       Date:  2017-10-10       Impact factor: 9.423

8.  In situ click chemistry generation of cyclooxygenase-2 inhibitors.

Authors:  Atul Bhardwaj; Jatinder Kaur; Melinda Wuest; Frank Wuest
Journal:  Nat Commun       Date:  2017-02-23       Impact factor: 14.919

9.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

10.  Small-molecule targeting of brachyury transcription factor addiction in chordoma.

Authors:  Tanaz Sharifnia; Mathias J Wawer; Ting Chen; Qing-Yuan Huang; Barbara A Weir; Ann Sizemore; Matthew A Lawlor; Amy Goodale; Glenn S Cowley; Francisca Vazquez; Christopher J Ott; Joshua M Francis; Slim Sassi; Patricia Cogswell; Hadley E Sheppard; Tinghu Zhang; Nathanael S Gray; Paul A Clarke; Julian Blagg; Paul Workman; Josh Sommer; Francis Hornicek; David E Root; William C Hahn; James E Bradner; Kwok K Wong; Paul A Clemons; Charles Y Lin; Joanne D Kotz; Stuart L Schreiber
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

View more
  1 in total

1.  Rare germline deleterious variants increase susceptibility for lung cancer.

Authors:  Jian Sang; Tongwu Zhang; Jung Kim; Mengying Li; Angela C Pesatori; Dario Consonni; Lei Song; Jia Liu; Wei Zhao; Phuc H Hoang; Dave S Campbell; James Feng; Monica E D'Arcy; Naoise Synnott; Yingxi Chen; Zeni Wu; Bin Zhu; Xiaohong R Yang; Kevin M Brown; Jiyeon Choi; Jianxin Shi; Maria Teresa Landi
Journal:  Hum Mol Genet       Date:  2022-10-10       Impact factor: 5.121

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.